ZACKS·2026-03-11 13:25Core Insights - Intuitive Surgical (ISRG) is reinforcing its leadership in robotic-assisted surgery, driven by strong procedure growth, global adoption, and the rollout of next-generation platforms [1][22] Financial Performance - In 2025, Intuitive Surgical reported a revenue increase of 21% to $10.1 billion, with procedures rising 19% year over year [1][10] - Pro forma EPS increased by more than 20% for the third consecutive year in 2025 [12] Procedure Growth - The adoption of da Vinci robotic systems is accelerating, with over 3.1 million patients treated in 2025 and more than 20 million procedures performed since inception [2][10] - Da Vinci procedures grew approximately 18%, while the Ion lung biopsy platform saw a 51% increase in procedures [4][10] - The SP platform recorded an impressive 87% growth in procedures in 2025 [8][10] Geographic Expansion - International da Vinci procedures increased by 23%, now accounting for roughly 35% of global procedures, indicating expanding adoption outside the United States [5][10] Technological Advancements - The launch of the da Vinci 5 system is a significant catalyst, with strong customer interest and higher utilization rates compared to previous generations [6][10] - The da Vinci 5 system integrates digital capabilities such as simulation and performance analytics, enhancing surgeon outcomes [7][10] Ecosystem Development - Intuitive Surgical is expanding its surgical ecosystem beyond da Vinci systems, with the Ion system gaining traction in lung cancer diagnostics and a global installed base nearing 1,000 systems [8][9] Market Position and Valuation - ISRG trades at a forward P/E of 47.08X, significantly higher than the industry average of 26.18X, reflecting its dominant market position and high operating margins of around 37% [15][16] Growth Estimates - Earnings estimates for 2026 have increased by 7.4% to $10.06 per share, while 2027 estimates improved by 5.6% to $11.41 [10]